Literature DB >> 26151123

Correlation of hip fracture with other fracture types: Toward a rational composite hip fracture endpoint.

Cathleen Colón-Emeric1, Carl F Pieper2, Janet Grubber3, Lynn Van Scoyoc3, Merritt L Schnell3, Courtney Harold Van Houtven4, Megan Pearson3, Joanne Lafleur5, Kenneth W Lyles6, Robert A Adler7.   

Abstract

PURPOSE: With ethical requirements to the enrollment of lower risk subjects, osteoporosis trials are underpowered to detect reduction in hip fractures. Different skeletal sites have different levels of fracture risk and response to treatment. We sought to identify fracture sites which cluster with hip fracture at higher than expected frequency; if these sites respond to treatment similarly, then a composite fracture endpoint could provide a better estimate of hip fracture reduction.
METHODS: Cohort study using Veterans Affairs and Medicare administrative data. Male Veterans (n=5,036,536) aged 50-99 years receiving VA primary care between 1999 and 2009 were included. Fractures were ascertained using ICD9 and CPT codes and classified by skeletal site. Pearson correlation coefficients, logistic regression and kappa statistics were used to describe the correlation between each fracture type and hip fracture within individuals, without regard to the timing of the events.
RESULTS: 595,579 (11.8%) men suffered 1 or more fractures and 179,597 (3.6%) suffered 2 or more fractures during the time under study. Of those with one or more fractures, the rib was the most common site (29%), followed by spine (22%), hip (21%) and femur (20%). The fracture types most highly correlated with hip fracture were pelvic/acetabular (Pearson correlation coefficient 0.25, p<0.0001), femur (0.15, p<0.0001), and shoulder (0.11, p<0.0001).
CONCLUSIONS: Pelvic, acetabular, femur, and shoulder fractures cluster with hip fractures within individuals at greater than expected frequency. If we observe similar treatment risk reductions within that cluster, subsequent trials could consider the use of a composite endpoint to better estimate hip fracture risk. Published by Elsevier Inc.

Entities:  

Keywords:  Correlation; Fractures; Osteoporosis; Veterans

Mesh:

Substances:

Year:  2015        PMID: 26151123      PMCID: PMC4772882          DOI: 10.1016/j.bone.2015.07.003

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  15 in total

1.  Using medical services claims to assess injuries in the elderly: sensitivity of diagnostic and procedure codes for injury ascertainment.

Authors:  R Tamblyn; T Reid; N Mayo; P McLeod; M Churchill-Smith
Journal:  J Clin Epidemiol       Date:  2000-02       Impact factor: 6.437

2.  Placebo-controlled trials in osteoporosis--proceeding with caution.

Authors:  Clifford J Rosen; Sundeep Khosla
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

3.  Prevalence of osteoporosis in men in a VA rehabilitation center.

Authors:  Arthur Swislocki; Jon A Green; Gerhard Heinrich; Charles A Barnett; Ivan D Meadows; Ernest B Harmon; Mary F Rank; Robert H Noth
Journal:  Am J Manag Care       Date:  2010-06       Impact factor: 2.229

4.  Risk factors for osteoporosis in a subgroup of elderly men in a Veterans Administration nursing home.

Authors:  Shing-Shing Yeh; Donna Phanumas; Alice Hafner; Michael W Schuster
Journal:  J Investig Med       Date:  2002-11       Impact factor: 2.895

5.  Unrecognized risks among Veterans with hip fractures: opportunities for improvements.

Authors:  Andrea Ohldin; James Floyd
Journal:  J South Orthop Assoc       Date:  2003

6.  Recommendations for the clinical evaluation of agents for treatment of osteoporosis: consensus of an expert panel representing the American Society for Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the National Osteoporosis Foundation (NOF).

Authors:  Stuart L Silverman; Steven R Cummings; Nelson B Watts
Journal:  J Bone Miner Res       Date:  2008-01       Impact factor: 6.741

7.  Identification and validation of vertebral compression fractures using administrative claims data.

Authors:  Jeffrey R Curtis; Amy S Mudano; Daniel H Solomon; Juan Xi; Mary Elkins Melton; Kenneth G Saag
Journal:  Med Care       Date:  2009-01       Impact factor: 2.983

8.  Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

Authors:  Matthew R Smith; Blair Egerdie; Narciso Hernández Toriz; Robert Feldman; Teuvo L J Tammela; Fred Saad; Jiri Heracek; Maciej Szwedowski; Chunlei Ke; Amy Kupic; Benjamin Z Leder; Carsten Goessl
Journal:  N Engl J Med       Date:  2009-08-11       Impact factor: 91.245

9.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Authors:  Steven R Cummings; Javier San Martin; Michael R McClung; Ethel S Siris; Richard Eastell; Ian R Reid; Pierre Delmas; Holly B Zoog; Matt Austin; Andrea Wang; Stepan Kutilek; Silvano Adami; Jose Zanchetta; Cesar Libanati; Suresh Siddhanti; Claus Christiansen
Journal:  N Engl J Med       Date:  2009-08-11       Impact factor: 91.245

10.  Bone mineral density scans in veterans.

Authors:  Elizabeth Bass; Etienne Pracht; Philip Foulis
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

View more
  3 in total

1.  Fracture Rates and Bone Density Among Postmenopausal Veteran and Non-Veteran Women From the Women's Health Initiative.

Authors:  Joanne LaFleur; Eileen Rillamas-Sun; Cathleen S Colón-Emeric; Kristin A Knippenberg; Kristine E Ensrud; Shelly L Gray; Jane A Cauley; Andrea Z LaCroix
Journal:  Gerontologist       Date:  2016-02

2.  Administrative health data: guilty until proven innocent. Response to comments by Levy and Sobolev.

Authors:  S D Berry; A R Zullo; K McConeghy; Y Lee; L Daiello; D P Kiel
Journal:  Osteoporos Int       Date:  2017-10-06       Impact factor: 4.507

3.  Factors Associated With Osteoporosis Care of Men Hospitalized for Hip Fracture: A Retrospective Cohort Study.

Authors:  Samantha L Solimeo; Kimberly McCoy; Heather Schacht Reisinger; Robert A Adler; Mary Vaughan Sarrazin
Journal:  JBMR Plus       Date:  2019-06-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.